Is wint a good stock to buy

**Windtree Therapeutics (WINT) does not appear to be a good stock to buy at the moment**. Here's why:

1. **Recent Price Movement**: The closing price of WINT on April 16, 2025, was $1.13, which represents a decrease of 4.24% from the last change. This indicates a recent negative trend in the stock's price.

|code|Ticker|Name|Date|Support Level|Resistance Level|market_code|
|---|---|---|---|---|---|---|
|WINT|WINT.O|Windtree|20250416|1.0300|1.1600|186|

2. **Technical Indicators Suggest Caution**: The stock's MACD is at 0.3, which is close to the neutral line and not indicative of a strong trend. The RSI is at 30.05, suggesting the stock is neither overbought nor oversold. The KDJ indicator is at 14.81, which could suggest that the stock is currently oversold and may rebound. However, the BOLL is at $1.42, which is relatively narrow, indicating limited volatility.

|code|Ticker|Name|Date|Boll|RSI|KDJ|MACD|market_code|
|---|---|---|---|---|---|---|---|---|
|WINT|WINT.O|Windtree|20250416|1.4240|30.0479|14.8064|0.2966|186|

3. **Moving Averages Show Weakness**: The 5-Day, 10-Day, and 20-Day moving averages are $1.26, $1.27, and $1.42, respectively. This indicates that the stock is trading below these short-term and medium-term moving averages, which could be a bearish signal.

|code|Ticker|Name|Date|Moving Average|market_code|
|---|---|---|---|---|---|
|WINT|WINT.O|Windtree|20250416|1.2620|186|

4. **Fund Flow is Negative**: The net fund flow is -$24920.23, and the net fund flow (block order) is -$23844.97. This indicates that there is significant selling pressure, which could be a red flag for investors.

|code|Ticker|Name|Date|Net Fund Flow|Net Fund Flow (Block Order)|market_code|
|---|---|---|---|---|---|---|
|WINT|WINT.O|Windtree|20250106|7967.9637|6413.0592|186|
|WINT|WINT.O|Windtree|20250107|82401.8997|76130.0987|186|
|WINT|WINT.O|Windtree|20250108|-49050.5443|-49050.5443|186|
|WINT|WINT.O|Windtree|20250110|-17412.111|-19063.2764|186|
|WINT|WINT.O|Windtree|20250113|620.6518|4374.2962|186|
|WINT|WINT.O|Windtree|20250114|35473.2511|34320.9687|186|
|WINT|WINT.O|Windtree|20250115|69104.6838|50548.5037|186|
|WINT|WINT.O|Windtree|20250116|-22520.1596|-27977.925|186|
|WINT|WINT.O|Windtree|20250117|23450.0621|21410.1753|186|
|WINT|WINT.O|Windtree|20250121|4502.4022|2460.7189|186|

5. **Strategic Initiatives**: While Windtree Therapeutics has made significant strides in clinical development and strategic planning, as evidenced by the SEISMiC Extension Phase 2 trial results and the SEISMiC C Phase 2 study initiation, the impact of these initiatives on the stock's short-term trend is unclear. The company's licensing deal with Evofem Biosciences could potentially lead to a positive impact on the stock, but this is yet to be seen.
6. **Analyst Sentiment is Neutral**: There are no available data on analyst price targets or consensus ratings, which makes it difficult to gauge the stock's potential upside or downside.

In conclusion, based on the available data, Windtree Therapeutics does not appear to be a good stock to buy at the moment. The stock's recent price movement, technical indicators, and fund flow data suggest bearishness. Without positive short-term forecasts or significant positive news, it is currently not a good time to buy WINT stock.